|
Advertising
Customer Service
• Register
|
By Shankar P."This technology could radically change the way patients are currently treated for weakened or fractured hips, vertebrae and acute traumatic long bone fractures," said Dr. Agnès Vignery, principal investigator at Yale University and senior author of the publication.
The researchers evaluated the effect of Fairfield-based Unigene''s technology and found "the procedure created new bone tissue that appears structurally and biologically normal," according to the statement. Additional studies that extend the results of this work in different animal models are ongoing.
Unigene focuses on the oral and nasal delivery of large-market peptide drugs. Its shares were unchanged at $1.95 in early trading.
Related Articles
